Cantor Reiterates Buy on Synergy Pharmaceuticals Inc Following 4Q:14 Update
Cantor analyst Irina Rivkind came out with a research note on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), after the company released its fourth-quarter results, posting a net loss of $30.6M and loss per share of ($0.32), coming in below the FactSet consensus loss per share estimate of ($0.27).
Rivkind noted, "Expenses somewhat above expectations in 4Q:14: Synergy reported a net loss of $30.6M and loss per share of ($0.32), coming in below the FactSet consensus loss per share estimate of ($0.27). Expenses increased in the quarter (R&D of $24.6M versus $20M in 3Q:14) and were likely associated with the launch of the IBS-C Phase III trial in December. The company's 10-K disclosed that plecanatide is now patent protected until 2031 by a method-of-use patent issued in March that meaningfully enhances the product's attractiveness to a potential partner, in our view. We continue to view Synergy as a potential takeout candidate and therefore base our PT on M&A valuation"
The analyst reiterated a Buy rating on the stock with an $8.50 price target, which represents a potential upside of 125.5% from where the stock is currently trading.
According to TipRanks.com, which measures analysts' and bloggers' success rate based on how their calls perform, analyst Irina Rivkind Koffler has a total average return of 38.0% and a 79.8% success rate. Koffler has a 2.7% average return when recommending SGYP, and is ranked #7 out of 3533 analysts.